Call Now

Human HER2 / ErbB2 Protein (ECD, domain IV) (His Tag)

CD340,HER-2,HER-2/neu,HER2,MLN 19,MLN19,NEU,NGL,TKR1

Catalog Number P10004-H08H4
Organism Species Human
Host Human Cells
Synonyms CD340,HER-2,HER-2/neu,HER2,MLN 19,MLN19,NEU,NGL,TKR1
Molecular Weight The recombinant human ERBB2 consists of 153 amino acids and predicts a molecular mass of 17.1 kDa.
predicted N Pro 489
SDS-PAGE
Purity > (48.9+40.2) % as determined by SDS-PAGE.
Protein Construction A DNA sequence encoding the human ERBB2 (AAA75493.1) (Pro489-Cys630) was expressed with a polyhistidine tag at the C-terminus.
Bio-activity
Research Area Cardiovascular |Angiogenesis |Growth Factor & Receptor |Receptor Tyrosine Kinase (RTK)
Formulation Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.
Reference
  • Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.